Ipsen had a robust presence at the 12th World Congress for Neurorehabilitation (WCNR) in Vienna, Austria and virtually, from 14-17 December 2022, further demonstrating the company’s long-standing partnership with the World Federation for Neurorehabilitation (WFNR) and ongoing commitment to neuroscience.
In addition to showcasing the company’s latest neuroscience clinical data, Ipsen hosted a satellite symposium entitled “About time: Optimising Long-Term Outcomes for Patients Treated with Botulinum Toxin”. Facilitated by global neuroscience experts Dr. Jorge Jacinto, Dr. Klemens Fheodoroff and Dr. Alberto Esquenazi, the session centred on new clinical data and around Ipsen’s patient-centric approach to educational training and the importance of focusing on long-term outcomes for patients treated with a botulinum toxin.
Data presented at WCNR 2022 included:
- A Phase IV, Prospective, Observational, Multicentre Study Evaluating the Effectiveness and Safety of abobotulinumtoxinA in Pediatric Lower Limb Spasticity (PLLS).
- A study exploring abobotulinumtoxinA efficacy and safety in children with upper limb spasticity previously treated with botulinum toxin.
- A study examining the change in Leg Activity Measure (LegA) sensitivity following treatment of lower limb spasticity with a single cycle of abobotulinumtoxinA in an ambulant population.
- Single centre, prospective, observational study methodology to assess the use of GripAble, a rehabilitation device, on patients with upper limb spasticity (ULS) receiving botulinum toxin A (BoNT-A).
- Baseline data from the AboLiSh study, exploring the most frequently injected muscles in patients undergoing treatment with abobotulinumtoxinA for lower limb spasticity in routine practice.
- The detrimental impact of the COVID-19 pandemic on the management of post-stroke spasticity in England.
Continuing to advance neuroscience and neurotoxin research
With over 25 years of experience in neurotoxins, neuroscience innovation remains central to the company’s future. Key data from Ipsen’s research and development programme reinforcing the company’s commitment to improving health outcomes for patients living with debilitating neurological disorders were at the WCNR. Clinical updates include a focus on the need to ensure treatment for spasticity is individualised, assessment of the impact of treatment with Dysport® (abobotulinumtoxinA) in pediatric and adult spasticity and a review of the impact of COVID-19 on stroke admissions and interventions in the UK.
“The breadth of data presented at the congress demonstrates our commitment to continued scientific innovation in neuroscience as well our focus on looking at patient care holistically to add value beyond our treatments. This aligns to our broader company strategy of thinking more holistically about how patients experience healthcare – not just how they experience a medicine – to advance neuroscience,” commented Steven Hildemann, Executive Vice President and Chief Medical Officer, Ipsen.
Committed to improving health outcomes
WCNR 2022 also marks the 10th anniversary of Ipsen’s Ixcellence Network®, an educational programme raising the standards of care for patients living with debilitating neurological disorders.
Since its launch, Ipsen has established 10 Ixcellence expert centres in Europe and Latin America, with nearly 800 physicians benefitting from the programme so far and improving the standard of care for thousands of patients with spasticity from around the world with its best-in-class injector training.
Hamzah Baig, Vice President, Global Medical Affairs, Neuroscience, Ipsen, said: “With comprehensive and wide-ranging cutting-edge content, including use of advanced guidance techniques and implementation of multi-disciplinary care, the Ixcellence Network® is the only programme of its kind to have articles published in peer-reviewed journals; it is the gold-standard for advanced training in treating cervical dystonia and focal spasticity.”
As part of their commitment to physician education, Ipsen delivered an interactive educational training session at the WCNR, tailored around the management of complex patient cases.